期刊文献+

磺脲类降糖药物的临床认识 被引量:6

The look at sulfonylurea compounds
原文传递
导出
摘要 磺脲类药物是最为古老的口服降糖药物之一,多年的临床研究对于磺脲类药物的疗效和安全性积累了丰富的经验,使其成为目前临床上最常应用的口服降糖药物之一。磺脲类药物不仅能促进胰岛B细胞释放胰岛素,还能产生减少肝脏对胰岛素的清除、抑制胰高糖素的生成等作用。目前磺脲类药物在2型糖尿病的治疗中占有重要的地位,但是近年来磺脲类药物引起低血糖、增重、心血管事件风险等副反应逐渐引起学界的重视。WENZHANG对磺脲类药物的作用机制、疗效、副反应和新近进展等方面做以综述。 Sulfonylurea compounds were the first oral antidiabetic agents in the world. They are important in optimal glucose control. Sulfonylureas not only have the function of stimulating insulin releasing from β-cells of pancreas, but also have some extrapancreatic effects, such as decreasing the clearance of hepatic insulin, reducing the secretion of glucagon in patients with type 2 diabetes mellitus and so on. Sulfonylurea compounds were the primary pharmacotherapy for type 2 diabetes mellitus patients, but their safety and clinical utility caused some controversy because of inducing the risks of hypoglycemia, gain of weight, causing cardiovascular disease outcomes and cancer in recent years. In this work, we reviewed the biological mechanisms of sulfonylureas, the efficacy of its oral taken in T2DM and the side effects of its usage and so on.
机构地区 卫生部北京医院
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第10期969-973,共5页 Chinese Journal of Practical Internal Medicine
关键词 磺脲类药物 额外的胰腺效应 疗效 副反应 Sulfonylurea extrapancreatic effects clinical utility side effects
  • 相关文献

参考文献25

  • 1Barzilai N,Groop PH,Groop L,DeFronzo RA.A novel mechanism of glipizide sulfonylurea action:decreased metabolic clearance rate of insulin[J].Acta Diabetol,1995,32:273-278.
  • 2Landstedt-Hallin L,Adamson U,Lins PE.Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes[J].J Clin Endocrinol Metab,1999,84:3140-3145.
  • 3Braak EW,Appelman AM,van der Tweel I,Erkelens DW,van Haeften TW.The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin induced hypoglycemia[J].Diabetes Care,2002,25:107-112.
  • 4Cryer PE.Minireview:glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes[J].Endocrinology,2012,153:1039-1040.
  • 5Rossetti L,Giaccari A,DeFronzo RA.Glucose toxicity[J].Diabetes Care,1990,13:610-630.
  • 6Mandarino LJ,Gerich JE.Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in noninsulin-dependent diabetes mellitus:evidence for improved insulin action at a post receptor site in hepatic as well as extrahepatic tissues[J].Diabetes Care,1984,7(Suppl 1):89-99.
  • 7Muller G.Dynamics of plasma membrace microdomains and crosstalk to the insulin signalling cascade[J].FEB S Lett,2002,531:81-87.
  • 8Scarsi M,Podvinecn M,Roth A,et al.Sulfonylureas and glinides exhibit peroxisome proliferator-actived receptor gamma activity:a combined virtual screening and biological assay approach[J].Mol pharmacol,2007,71(2):398-406.
  • 9Inzucchi SE,Bergenstal RM,Buse JB,et al.Management of hyperglycemia in type 2 diabetes:a patient-centered approach:position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J].Diabetes Care,2012,35:1364-1379.
  • 10Kahn SE,Haffner SM,Heise MA,et al.Glycemic durability of rosiglitazone,metformin,or glyburide monotherapy[J].N Eng Med,2006,355:2427-2443.

同被引文献60

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部